CG
ALNY icon

Cutler Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cutler Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,000
Closed -$76K – 3563
2023
Q3 		$76K Buy
+3,000
New +$572K 0.01% 1269
2023
Q2 		– Sell
-1,700
Closed -$4K – 3512
2023
Q1 		$4K Sell
1,700
-14,900
-90% -$3.13M ﹤0.01% 2787
2022
Q4 		$5K Buy
16,600
+1,100
+7% +$235K ﹤0.01% 3117
2022
Q3 		$32K Sell
15,500
-3,900
-20% -$744K ﹤0.01% 2230
2022
Q2 		$305K Sell
19,400
-15,400
-44% -$2.18M 0.02% 758
2022
Q1 		$304K Buy
34,800
+1,500
+5% +$229K 0.02% 932
2021
Q4 		$213K Buy
+33,300
New +$6.19M 0.01% 1267
2021
Q3 		– Sell
-9,500
Closed -$76K – 5636
2021
Q2 		$76K Buy
+9,500
New +$1.39M ﹤0.01% 2112
2020
Q2 		– Sell
-900
Closed -$11K – 4314
2020
Q1 		$11K Buy
+900
New +$104K ﹤0.01% 2643
2019
Q4 		– Sell
-3,000
Closed -$27K – 3918
2019
Q3 		$27K Sell
3,000
-10,000
-77% -$791K ﹤0.01% 1955
2019
Q2 		$85K Buy
13,000
+8,000
+160% +$614K 0.01% 1186
2019
Q1 		$53K Sell
5,000
-5,300
-51% -$443K 0.01% 1380
2018
Q4 		$212K Sell
10,300
-2,200
-18% -$169K 0.02% 616
2018
Q3 		$128K Buy
12,500
+6,700
+116% +$674K 0.01% 1060
2018
Q2 		$111K Sell
5,800
-8,000
-58% -$793K 0.01% 1086
2018
Q1 		$147K Sell
13,800
-35,800
-72% -$4.62M 0.01% 970
2017
Q4 		$142K Sell
49,600
-84,100
-63% -$10.6M 0.01% 1164
2017
Q3 		$101K Buy
133,700
+74,300
+125% +$6.34M ﹤0.01% 1665
2017
Q2 		$164K Buy
59,400
+16,000
+37% +$1.02M 0.01% 1442
2017
Q1 		$183K Sell
43,400
-5,800
-12% -$268K 0.01% 1263
2016
Q4 		$360K Buy
49,200
+18,000
+58% +$754K 0.01% 892
2016
Q3 		$200K Sell
31,200
-1,000
-3% -$70.6K 0.01% 1207
2016
Q2 		$279K Sell
32,200
-400
-1% -$25.2K 0.01% 899
2016
Q1 		$275K Buy
32,600
+17,500
+116% +$1.16M 0.02% 820
2015
Q4 		$65K Buy
+15,100
New +$1.4M ﹤0.01% 2191

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Cutler Group's ALNY Position: Q4 2023 in Review

Cutler Group sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2023, closing a stake of 1,500 shares — an estimated $265K sold.

Cutler Group first reported a position in ALNY in Q4 2015 and held it in 21 quarters. The position peaked at $5.67M in Q4 2017. 498 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.

  • Cutler Group reported no remaining Alnylam Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 1,500 Alnylam Pharmaceuticals shares in Q4 2023, an estimated $265K.
  • Cutler Group first reported a position in Alnylam Pharmaceuticals in Q4 2015 and held it in 21 quarters.
  • Cutler Group's Alnylam Pharmaceuticals position peaked at $5.67M in Q4 2017.
  • 498 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.